Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1652 1683
This examiner grants 65% of resolved cases
Richard G Hutson is an examiner in Tech Center 1600, working in Art Unit 1652. With 905 resolved cases, the examiner has an extensive record that provides highly reliable metrics. This volume of 905 cases ensures that the observed trends are stable and representative of the examiner's long-term behavior. The data shows an allowance rate of 65.0 percent.
The median time to allowance is 1277 days. This 1277-day timeline indicates a relatively long prosecution process, which practitioners should communicate to their clients. Despite the duration, the 65.0 percent allowance rate suggests a reasonable probability of success. Strategy in Art Unit 1652 must be planned around this 1277-day median timeframe.
A standout metric for this examiner is the interview lift of 53.1 percent. This exceptionally high lift indicates that interviews are a critical tool for securing an allowance. A 53.1 percent increase in the likelihood of success following an interview is one of the strongest signals in the data. Practitioners should prioritize direct engagement with the examiner to overcome the 65.0 percent base rate and navigate the 1277-day cycle in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18596176 | MODIFIED ENZYMES | Final Rejection | Oxford Nanopore Technologies PLC |
| 18065644 | FABRIC AND HOME CARE COMPOSITION INCLUDING A PROTEASE | Non-Final OA | The Procter & Gamble Company |
| 18538539 | REVERSE TRANSCRIPTASE VARIANTS FOR IMPROVED PERFORMANCE | Non-Final OA | 10X GENOMICS, INC. |
| 18384537 | FUSION RT VARIANTS FOR IMPROVED PERFORMANCE | Final Rejection | 10x Genomics, Inc. |
| 18266787 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | Final Rejection | THE UNIVERSITY OF BRITISH COLUMBIA |
| 16626396 | NOVEL TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | Final Rejection | President and Fellows of Harvard College |
| 18349707 | NOVEL CAS13B ORTHOLOGUES CRISPR ENZYMES AND SYSTEMS | Non-Final OA | Massachusetts Institute of Technology |
| 16954032 | CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18563157 | TRANSAMINASE ENZYMES FOR THE TRANSAMINATION OF (1S,5R)-6,8-DIOXABICYCLO[3.2.1]OCTAN-4-ONE | Non-Final OA | MERCK SHARP & DOHME LLC |
| 18740839 | Method For Improving Mitochondrial Functions | Non-Final OA | TOHOKU UNIVERSITY |
| 18186443 | COMPOSITIONS AND METHODS FOR CAS9 MOLECULES WITH IMPROVED GENE EDITING PROPERTIES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18288490 | NOVEL PROTEIN HAVING METHANE OXIDATION ACTIVITY | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18547525 | DNASE VARIANTS | Non-Final OA | Novozymes A/S |
| 18263339 | ALPHA-AMYLASE VARIANTS | Final Rejection | Novozymes A/S |
| 18043515 | POLYESTER DEGRADING PROTEASE VARIANTS | Final Rejection | Novozymes A/S |
| 19008032 | Production Of Non-Native Monounsaturated Fatty Acids In Bacteria | Non-Final OA | Genomatica, Inc. |
| 18600046 | MODIFIED O-METHYLTRANSFERASES USEFUL FOR PRODUCTION OF O-METHYLATED PHENOLIC NATURAL PRODUCTS | Non-Final OA | The University of Hong Kong |
| 18538262 | ALTERED CYTIDINE DEAMINASES AND METHODS OF USE | Final Rejection | ILLUMINA, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy